Bandhan Healthcare Fund - Regular Plan - Growth

    Compare Fund
    Equity · Sector Specific - PharmaNAV₹10.608 Oct 2026AUM₹332 croreExpense ratio2.75%1YN/A3YN/A5YN/A

    Investment Objective

    The Scheme Seeks To Generate Long-Term Capital Appreciation By Investing Predominantly In Equity And Equity-Related Instruments Of Companies Engaged In Healthcare, Pharma And Allied Sectors.

    Performance vs Benchmark

    FundNAV as of 8 Oct 2026

    Hold this fund?

    See it next to everything else you own: every holding in one place, how it is allocated and how it is really doing.

    Review my portfolio Compare with other funds

    At a glance

    If you had invested

    Period

    Loading NAV history.

    Portfolio

    As of 8 Oct 2026

    Asset class

    • Equity96.0%
    • Others4.0%

    Market cap

    • Large Cap30.1%
    • Mid Cap31.9%
    • Small Cap33.9%
    • Others4.0%

    Key figures

    P/E ratio
    49.1
    Fund size
    ₹332 crore
    Expense ratio
    2.75% a year

    How it compares

    Trailing Returns

    1M3M6MYTD1Y3Y5Y7Y10Y
    This fund-3.38%+0.50%+18.73%+11.10%N/AN/AN/AN/AN/A

    Calendar Year Returns vs Benchmark

    Comparison with BSE Healthcare Index

    More detail

    Monthly returns, rolling returns, risk measures and the full NAV history.

    About Bandhan Healthcare Fund Regular Plan Growth

    Bandhan Healthcare Fund Regular Plan Growth is a Sector Specific - Pharma equity fund from Bandhan AMC Limited, launched on 24 Nov 2025. Its benchmark is the BSE Healthcare Index. The expense ratio is 2.75% a year. It manages ₹332 crore. The NAV was ₹10.60 on 8 Oct 2026.

    See returns as a table

    Calendar year returns against the BSE Healthcare Index

    From 2025 to 2026, the fund returned more than the BSE Healthcare Index in 1 of 2 calendar years. The 2026 figure is year to date.

    Year20252026 YTD
    This fund-1.71%+11.10%
    Benchmark-3.26%+19.04%

    Compare every pharma and healthcare fund on returns, volatility, worst fall and cost.

    Other sector specific - pharma funds

    • Nippon India Pharma Fund
    • ICICI Prudential Healthcare Fund
    CompareReview my portfolio

    Wealth Home

    Track & analyse your Wealth Home

    Connect your mutual funds to see every holding in one place, how it is allocated, and how it is really doing.

    Review my portfolioTalk to an adviser
    QR code to download the RuDo Wealth app

    Scan to connect on the app

    iOS and Android. See your whole portfolio in a minute.

    Investing from the UAE. NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. Some fund houses restrict residents of the US and Canada. India taxes equity fund gains at 20% on units held 12 months or less and 12.5% above ₹1.25 lakh a year after that, plus cess and any surcharge, deducted when an NRI redeems. The UAE has no personal income tax and the India UAE treaty may apply, so confirm your position with a tax adviser.

    Data from RuDo Wealth fund analytics, NAV as of 8 Oct 2026; benchmark as named by Bandhan AMC Limited. India: RuDo Wealth Investment Advisory, SEBI Registered Investment Adviser, registration INA000019503. UAE: RuDo Digital Wealth, FSRA Financial Services Permission 220155, Category 3C (Retail), ADGM. General information, not a recommendation to buy or sell this fund. Past performance does not indicate future returns.

  1. SBI Healthcare Opportunities Fund
  2. DSP Healthcare Fund
  3. Mirae Asset Healthcare Fund
  4. HDFC Pharma and Healthcare Fund
  5. Tata India Pharma & Healthcare Fund
  6. UTI Healthcare Fund

    7. All funds from Bandhan AMC